<DOC>
	<DOC>NCT01775631</DOC>
	<brief_summary>The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Rituximab in patients with B-cell Non-Hodgkins Lymphoma</brief_summary>
	<brief_title>Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma</brief_title>
	<detailed_description>Intervention model: Dose Escalation (part 1) of study= Sequential Design; Dose Expansion (part 2) of study= Parallel Design</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Clinical diagnosis of relapsed/refractory Bcell Malignancies (BNonHodgkins Lymphoma (NHL)) per International Workshop Group (IWG) Progressed or refractory to at least 1 prior line of standard therapy Subjects in Expansion cohorts are restricted to relapsed/refractory diffuse large Bcell lymphoma (DLBCL) or Follicular Lymphoma (FL) subjects who are either relapsed or refractory to prior rituximab or ritxumabcontaining chemotherapy regimens Follicular Lymphoma (FL) must have at least 1 lesion that can be biopsied at screening and on treatment Eastern Cooperative Oncology Group (ECOG) of 0 to 1 Active or progressing brain metastases Other concomitant malignancies (with some exceptions per protocol) Active or history of autoimmune disease Positive test for human immunodeficiency virus (HIV) 1&amp;2 or known Acquired immune deficiency syndrome (AIDS) History of any hepatitis (A, B or C) History of grade 34 drugrelated hepatitis Known current drug or alcohol abuse Active tuberculosis (TB) Prior therapy with any antibody/drug that targets the T cell coregulatory proteins, including but not limited to, antiCD137, Anti Cytotoxic T lymphocyteassociated antigen 4 (antiCTLA4) or AntiGlucocorticoidinduced tumor necrosis factor receptor (antiGITR). However, AntiProgrammed Death1 (antiPD1), AntiProgrammed DeathLigand1 (antiPDL1) are permissible as prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>